By Aidan Sowa, CEO and Founder, Frontier Industries | October 2026
Pharmaceutical communications used to be a conversation among professionals: journals, congresses, a specialist sales force, and regulators who read everything twice. The public has joined that conversation permanently, armed with prices, trial registries and grievances, and it does not trust you. KFF polling in 2025 found only 21 percent of adults trust pharmaceutical companies to act in the public interest (KFF, 2025). This guide is about choosing an agency for that reality: launch excellence under advertising law, evidence communication under political fire, and trust rebuilt one documented claim at a time. The science got you approved. It will not get you believed.
Key numbers for this decision:
- 55: novel drugs approved by the FDA Center for Drug Evaluation and Research in 2023 (FDA, 2024)
- 21 percent: adults who trust pharmaceutical companies to act in the public interest (KFF, 2025)
- 36: of the 55 novel approvals in 2023 that used at least one expedited FDA programme (FDA CDER, 2024)
I Discrimen
Your product is evidence, and your communications are regulated speech
No other industry in this series works under this double condition. Every claim you make about a medicine is bounded by the approved label, policed by the FDA Office of Prescription Drug Promotion, and archived by competitors and plaintiffs. At the same time, your real product in the public mind is not the molecule. It is the credibility of the evidence behind it: trial design, endpoints, population, limitations, spoken aloud.
Agencies divide sharply on whether they understand this. Brand agencies see a launch. Healthcare agencies see a label negotiation with a communications plan attached. The second view is correct, and it reorganises everything: medical, legal and regulatory review is not a delay in your process, it is your process; the substantiation file is not paperwork, it is the campaign; and the most persuasive sentence you own is usually the limitation your competitors were afraid to say.
Evidence first, eloquence second, volume last. In pharma the order is not a preference. It is the licence to operate.
Ask finalists to walk a single claim from data to published sentence, naming every review step and who can kill it. Firms that describe a gauntlet are describing your actual life. Firms that describe a fast lane are describing somebody else enforcement letter.
II Machina
Three clocks run your communications, and they never synchronise
The regulatory clock runs on filings, advisory committees and approval dates, including the 55 novel drugs the FDA approved in 2023, more than half of them for rare diseases (FDA, 2024). The evidence clock runs on data readouts, congress presentations and journal publication, moments when your science is repriced in public in an afternoon. The political clock runs on pricing debates, election cycles and access stories, and it can seize any week without asking the other two.
An agency must staff all three clocks at once. Regulatory fluency for the milestone calendar. Scientific translation for readout days, when a hazard ratio has to become a sentence a patient advocate and a financial journalist can both carry away accurately. And issues management for the political weather, because the week your launch succeeds is also the week your price becomes a story.
The firms that fail here usually fail by clock: a consumer style launch plan wandering into a readout, a regulatory team asleep during a pricing storm. In the pitch, set one scenario per clock and watch whether the same senior people can move between them. The seams between clocks are where pharma reputations tear.
Trial transparency runs underneath all three clocks as a permanent fourth obligation. Registration and results reporting on public registries are legal duties, but they are also read as character evidence by the patient communities and clinicians you most need. A company whose results, good and bad, appear on time and in full builds a file that pays out at every future readout. A company that treats disclosure as a minimum compliance exercise, late and grudging, teaches the same audiences to assume the worst about data they cannot see. Your agency should own the disclosure calendar as a communications asset, not merely track it as a regulatory chore.
III Exemplum
The expedited approval era made explanation a core competence
Thirty six of the 55 novel drugs approved in 2023 used at least one expedited programme, and the FDA approved 35 of the 55 before any other country (FDA CDER, 2024). Speed is now normal, and speed creates an explanation debt. Accelerated and priority pathways rest on surrogate endpoints, confirmatory trials and judgement calls that specialists understand and publics experience as shortcuts. Every fast approval therefore arrives with a question attached: was this rigor, or was this haste.
Companies that prepay the explanation do fine. They publish the pathway logic in plain language at approval, name the confirmatory commitments and their dates, and brief patient communities before the sceptics frame the story. Companies that treat the approval release as a victory lap meet the question later, in worse company, with a congressional hearing or a payer dossier quoting their own silence.
The lesson generalises to every data readout and label expansion you will ever announce. In this industry, unexplained good news decays into suspicion on a schedule of about one news cycle. Your agency should treat explanation not as the press release final paragraph but as a standing programme, with the confirmatory calendar published and kept like a promise.
IV Damnum
Distrust is your tax rate, and it is levied on every transaction
Start with the number again: 21 percent of the public trusts your industry to act in its interest, against 70 percent who trust doctors and health care providers (KFF, 2025). That gap is not a mood. It is a structural cost. It raises the evidence bar for every claim, shortens the leash in every negotiation with payers and policymakers, and means your patient stories are discounted before they are heard, assumed to be bought, because sometimes they have been.
It also distorts internal decisions. Companies that feel besieged either go silent, surrendering the narrative to critics, or go loud, buying awareness that converts at miserable rates because the audience dislikes the messenger. Both responses waste the one asset that actually compounds: documented candour. Pricing rationale explained before it is attacked. Trial failures published with the successes. Patient support programmes described in numbers, not adjectives.
The tax is also personal for your spokespeople. Scientists and executives who carry the company case in public get treated as defendants in interviews that have little to do with their own data, because the industry record walks into the room before they do. Preparation for that reality, hostile question drills, values language rehearsed until it is reflex, evidence at the fingertips, is a core agency duty in this sector, not executive polish. Leaders who are underprepared do not just lose interviews. They confirm the caricature, and the caricature is what the next decade of your communications budget will be spent refuting.
An agency that proposes to fix trust with a campaign has not understood the tax. Trust at this level is repaid in instalments of behaviour, and the agency job is to make each instalment visible, verifiable and impossible to mistake for theatre. Choose the firm that talks about evidence systems, not image.
V Genus
The pharma agency market, by actual discipline
| Agency type | Core strength | Structural weakness |
|---|---|---|
| Global healthcare network practice | Launch scale, regulatory depth, multi market coordination | Senior attention follows the largest brands; mid size products get the B team |
| Specialist medical communications firm | Evidence translation, publication planning, congress craft | Weaker consumer and political instincts |
| Public affairs led firm | Pricing and access storms, policymaker credibility | Launch sparkle and patient community warmth |
| Patient advocacy and community agency | Authentic community trust, unbranded disease education | Scale and regulatory horsepower must be verified, not assumed |
| Consumer brand agency with health desk | Disease awareness creativity | Label discipline is learned on your budget or not at all |
Most serious launches need a lead from the first two rows with the third on call for the pricing weather. The arrangement matters less than the seams: one claims register across every firm, one MLR process with teeth, and a single senior owner for the day the three clocks collide.
Interrogate the roster, not the reel. Ask which named individuals ran the last comparable launch, what their regulatory affairs counterparts said about working with them, and whether those individuals are contracted to your account or merely to the pitch.
VI Regio
Segment by therapy area and lifecycle, because the rules of belief change
An oncology launch, a rare disease approval and a primary care brand in its tenth year are three different communications businesses. Oncology lives on data cut precision and key opinion leader credibility. Rare disease lives on community trust built years before approval, in registries, listening and support that cannot be faked at launch. Mature primary care lives on access, adherence and defending share against a political headwind.
Lifecycle cuts across all of it. Pre approval, your job is disease education and expectation setting inside strict promotional boundaries. At launch, evidence translation and access explanation dominate. Post launch, real world evidence, safety communication and lifecycle stories carry the brand. An agency that pitches one programme for all three phases has not run a product through them.
Geography is regulatory, not decorative. The United States and New Zealand stand nearly alone in permitting direct to consumer prescription advertising, and global firms must be able to run compliant unbranded and branded work across regimes without bleeding claims across borders on social platforms that ignore borders. Ask for their claim segregation system by market. It is a boring question that prevents spectacular fines.
VII Occasio
The opening: candour about limits is the last underpriced asset in pharma
Every competitor publishes benefits. Almost nobody publishes, clearly and early, what their medicine does not do, who it is not for, and what remains unknown. Yet that is the content that clinicians respect, journalists trust and patient communities circulate, because it costs the publisher something and therefore proves something. In an industry trusted by a fifth of the public, costly candour is the only currency that still buys belief.
The practical form is a limitations habit: every major claim paired with its boundary, every surrogate endpoint explained with its confirmatory plan, every access programme published with eligibility in plain words. Agencies that build this habit into templates, not heroics, give you a voice no rival can copy quickly, because copying it requires their behaviour to change too.
This is also, quietly, your best regulatory strategy. Companies whose public record shows restraint and completeness meet reviewers, payers and legislators from a different starting position than companies whose record is a highlight reel. Reputation in pharma is a long file. Write it deliberately.
Start the habit where it is cheapest: the next routine announcement. Pair the headline result with its boundary in the same release, in the same type size, and brief it that way to every audience. Within a year the pattern becomes your signature, and signatures are what communications is actually for. A company recognised for how it tells the truth has an asset that survives a failed trial, a patent cliff and a change of chief executive, because it belongs to the record rather than to any single product story.
VIII Consilium
Score the decision on evidence discipline first
| Criterion | Weight | Proof required |
|---|---|---|
| MLR and label discipline | 25 percent | Their claims register and review workflow, with kill authority named |
| Evidence translation | 25 percent | A past readout explained accurately for three audiences |
| Issues and pricing readiness | 20 percent | Scenarios run, spokespeople trained, documents pre drafted |
| Patient community authenticity | 15 percent | Relationships held in their own right, with disclosure standards |
| Launch operations | 10 percent | Day one war room plan across regulatory, evidence and political clocks |
| Global claim segregation | 5 percent | Market by market compliance system for social content |
Contract accordingly: substantiation files as deliverables, advisory board and patient engagement disclosure rules as exhibits, and a standing quarterly review of live claims against labels that will have moved. Your label will change more often than your agency contract does. Govern for that.
The companion guide for biotechnology companies covers the earlier stage end of this industry, and the public relations services page sets out a governance model in full.
Frequently asked questions
When should we appoint an agency relative to approval?
Eighteen to twenty four months before expected approval for anything with a community or a contested evidence story, because disease education, community trust and publication planning cannot be compressed into the launch quarter. For straightforward line extensions, a year may do. Agencies appointed at approval inherit narratives written by everyone who arrived earlier, including your critics.
How do we handle patient stories without buying belief?
Disclose everything: support given, payments made, review rights agreed, in the content itself and not in a footnote graveyard. Then choose stories for what they teach about living with the condition, not for gratitude to the brand. The communities you most need can detect a purchased testimonial at fifty paces, and the detection becomes the story.
What belongs in a readout day plan?
Embargo discipline, three audience translations of the same data written in advance, the limitations paragraph approved before the headline, clinician and patient community briefings sequenced honestly, and a holding line for the questions the data cannot answer. If the plan fits on one slide, it is not a plan. It is a hope with a date.
How should we communicate price?
Before somebody else does, with the reasoning in plain language: what the therapy replaces, what it costs the system over time, what support exists for patients who cannot pay, and where the genuine uncertainties are. Silence on price is read as shame, and shame is read as guilt. The companies that explain early do not win the argument. They earn the right to be in it.
Can disease awareness campaigns run before approval?
Yes, unbranded and genuinely educational, within strict boundaries: no product claims, no implied identification of an unapproved therapy, and medical review as rigorous as for branded work. The discipline is worth it because the community relationships built pre approval are the ones that survive the pricing storm at launch.
What should we measure quarterly?
Claim accuracy audit results first: live claims against current labels, corrections issued, review cycle times. Then understanding measures among clinicians, patient communities and payers, tested rather than assumed. Reach and share of voice go in the appendix, where vanity belongs in a regulated industry.
How this guide was built
This guide draws on FDA approval reporting for 2023, KFF trust polling from 2025, and FDA prescription drug promotion resources, listed below. It describes selection principles for communications partners and is not legal advice on promotion; your regulatory counsel governs live claims. Market specifics shift with each label, each readout and each political season, which is precisely the condition this framework is built for.
IX Incipe
Where Frontier Industries fits
Frontier Industries builds pharmaceutical work around the claims register and the limitations habit: evidence translated faithfully, prices explained before they are attacked, and communities engaged with disclosure as a point of pride. The resources library holds the full sector series and the team is introduced on the about page.
If your team is choosing now, bring your toughest pending claim and your last readout coverage to one conversation: start an industry campaign enquiry or call 401-219-4207.
Sources
1. FDA, Novel Drug Approvals for 2023, Center for Drug Evaluation and Research. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023 2. FDA, New Drug Therapy Approvals 2023 report, including expedited programme and first cycle data. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/new-drug-therapy-approvals-2023 3. KFF, Poll finds low trust in pharmaceutical companies and health agencies independence concerns, 2025. https://www.kff.org/health-information-trust/kff-poll-finds-that-most-adults-lack-confidence-in-key-health-agencies-to-act-independently/ 4. KFF, Doctors remain the most trusted source of health information, 2025. https://www.kff.org/health-information-trust/new-kff-poll-shows-public-divided-when-it-comes-to-trusting-federal-health-agencies-for-reliable-information/ 5. FDA, Office of Prescription Drug Promotion, guidance and enforcement resources. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-prescription-drug-promotion-opdp 6. PhRMA, industry research and policy resources. https://phrma.org/ 7. ClinicalTrials.gov, registry and results reporting requirements for clinical trials. https://clinicaltrials.gov/ 8. Edelman, Trust Barometer, pharmaceutical and health sector trust findings. https://www.edelman.com/trust-barometer 9. Pharmaceutical Technology, CDER approved 55 novel drugs in 2023, coverage of FDA reporting. https://www.pharmtech.com/view/cder-approved-55-novel-drugs-in-2023 10. HHS Office for Civil Rights, privacy guidance relevant to patient engagement and testimonials. https://www.hhs.gov/hipaa/index.html